Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lilit Karapetyan, Jason J Luke & Diwakar Davar. (2020) Toll-Like Receptor 9 Agonists in Cancer. OncoTargets and Therapy 13, pages 10039-10060.
Read now
Read now
Guoqun Wang, Jiaojiao Zhao, Meiling Zhang, Qian Wang, Bo Chen, Yayi Hou & Kaihua Lu. (2019) Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation. International Journal of Nanomedicine 14, pages 4503-4515.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Florine Obrist, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Isabelle Cremer, Jan Henrik ter Meulen, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:6.
Read now
Read now
Articles from other publishers (27)
Marcelo V. Negrao, Vassiliki A. Papadimitrakopoulou, Andrew C. Price, Alda L. Tam, Muhammad Furqan, Sandeep T. Laroia, Erminia Massarelli, Jose Pacheco, John V. Heymach, Anne S. Tsao, Gary V. Walker, Lalit Vora, David Mauro, Heather Kelley, James E. Wooldridge, Arthur M. Krieg & Jiaxin Niu. (2023) Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC. JTO Clinical and Research Reports 4:3, pages 100423.
Crossref
Crossref
Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P Brown & David Goldstein. (2023) Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. Journal for ImmunoTherapy of Cancer 11:1, pages e006136.
Crossref
Crossref
Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You & Yang Zhao. (2022) Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials. Frontiers in Oncology 11.
Crossref
Crossref
Dipyaman GangulyDipyaman Ganguly. 2022. Plasmacytoid Dendritic Cells. Plasmacytoid Dendritic Cells
147
160
.
Ignacio Melero, Eduardo Castanon, Maite Alvarez, Stephane Champiat & Aurelien Marabelle. (2021) Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nature Reviews Clinical Oncology 18:9, pages 558-576.
Crossref
Crossref
Shuhei Teranishi, Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Sousuke Kubo, Yuji Shibata, Masaki Yamamoto, Makoto Kudo, Hongmei Piao & Takeshi Kaneko. (2020) Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer. Thoracic Cancer 11:4, pages 983-992.
Crossref
Crossref
Zahra Aryan, Mahsa Keshavarz-Fathi, Håkan Mellstedt & Nima Rezaei. 2020. Cancer Immunology. Cancer Immunology
1
48
.
Ze-Rui Zhao, Yao-Bin Lin, Calvin S.H. Ng, Rong Zhang, Xue Wu, Qiuxiang Ou, Wendan Chen, Wen-Jie Zhou, Yong-Bin Lin, Xiao-Dong Su, Yang W. Shao & Hao Long. (2019)
Mutation Profile of Resected
EGFR
-Mutated Lung Adenocarcinoma by Next-Generation Sequencing
. The Oncologist 24:10, pages 1368-1374.
Crossref
Crossref
Caiqi Liu, Ci Han & Jinfeng Liu. (2019) The Role of Toll-Like Receptors in Oncotherapy. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 27:8, pages 965-978.
Crossref
Crossref
Shang-Gin Wu & Jin-Yuan Shih. (2018) Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Molecular Cancer 17:1.
Crossref
Crossref
Chong Hyun Suh, Hye Sun Park, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu & Mizuki Nishino. (2018) Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. Lung Cancer 123, pages 60-69.
Crossref
Crossref
Mahaveer Singh & Hemant R. Jadhav. (2018) Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discovery Today 23:3, pages 745-753.
Crossref
Crossref
Jianwei Zhu, Rui Li, Eva Tiselius, Raheleh Roudi, Olivia Teghararian, Chen Suo & Huan Song. (2017) Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Yildian Díaz-Rodríguez, Paulo Cordeiro, Assila Belounis, Sabine Herblot & Michel Duval. (2017) In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells. Cancer Immunology, Immunotherapy 66:10, pages 1307-1320.
Crossref
Crossref
Jian-Wei Gao, Ping Zhan, Xiang-Yu Qiu, Jia-Jia Jin, Tang-Feng Lv & Yong Song. (2017) Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. Oncotarget 8:42, pages 73258-73270.
Crossref
Crossref
Thomas Mathew, Attila Á. Papp, Farzaneh Paknia, Santos Fustero & G. K. Surya Prakash. (2017) Benzodiazines: recent synthetic advances. Chemical Society Reviews 46:10, pages 3060-3094.
Crossref
Crossref
H. Shirota & D.M. Klinman. 2017. Immunopotentiators in Modern Vaccines. Immunopotentiators in Modern Vaccines
163
198
.
Dennis M. Klinman, Takashi Sato & Takeshi Shimosato. (2015) Use of nanoparticles to deliver immunomodulatory oligonucleotides. WIREs Nanomedicine and Nanobiotechnology 8:4, pages 631-637.
Crossref
Crossref
Marie Jordan & David J. Waxman. (2016) CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Letters 373:1, pages 88-96.
Crossref
Crossref
Emma M. Conway, Larissa A. Pikor, Sonia H. Y. Kung, Melisa J. Hamilton, Stephen Lam, Wan L. Lam & Kevin L. Bennewith. (2016) Macrophages, Inflammation, and Lung Cancer. American Journal of Respiratory and Critical Care Medicine 193:2, pages 116-130.
Crossref
Crossref
Lysanne Lievense, Joachim Aerts & Joost Hegmans. 2016. Lung Cancer and Personalized Medicine. Lung Cancer and Personalized Medicine
59
90
.
Takashi Sato, Takeshi Shimosato, Atsuhisa Ueda, Yoshiaki Ishigatsubo & Dennis M. Klinman. (2015) Intrapulmonary Delivery of CpG Microparticles Eliminates Lung Tumors. Molecular Cancer Therapeutics 14:10, pages 2198-2205.
Crossref
Crossref
Regina Heidenreich, Edith Jasny, Aleksandra Kowalczyk, Johannes Lutz, Jochen Probst, Patrick Baumhof, Birgit Scheel, Söhnke Voss, Karl-Josef Kallen & Mariola Fotin-Mleczek. (2015) A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. International Journal of Cancer 137:2, pages 372-384.
Crossref
Crossref
G. K. Surya Prakash, Attila Papp, Socrates B. Munoz, Nathan May, John-Paul Jones, Ralf Haiges, Pierre Mothé Esteves & Thomas Mathew. (2015) Lewis Acid Catalyzed Condensation-Cyclization Cascade: Direct Synthesis of Di/Trifluoromethyl-1,2,3,4-tetrahydroquinazolines. Chemistry - A European Journal 21:28, pages 10170-10178.
Crossref
Crossref
Krishan K. Thakur, Nityanand B. Bolshette, Cristiana Trandafir, Vinayak S. Jamdade, Alexandru Istrate, Ranadeep Gogoi & Andrei Cucuianu. (2015) Role of toll-like receptors in multiple myeloma and recent advances. Experimental Hematology 43:3, pages 158-167.
Crossref
Crossref
Zahra Aryan, Håkan Mellstedt & Nima Rezaei. 2015. Cancer Immunology. Cancer Immunology
1
39
.
Davide Melisi, Melissa Frizziero, Anna Tamburrino, Marco Zanotto, Carmine Carbone, Geny Piro & Giampaolo Tortora. (2014) Toll-Like Receptor 9 Agonists for Cancer Therapy. Biomedicines 2:3, pages 211-228.
Crossref
Crossref